ALX Oncology (ALXO) News Today $0.70 +0.00 (+0.54%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.69 -0.01 (-1.82%) As of 08/7/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period ALX Oncology Holdings Inc. to Report Second Quarter 2025 Financial Results and Business Update on August 12, 2025August 5 at 8:15 AM | quiverquant.comQALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025August 5 at 8:00 AM | globenewswire.comALX Oncology Holdings Inc. (ALXO) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comALX Oncology to Present at the Jefferies 2025 Global Healthcare ConferenceMay 30, 2025 | globenewswire.comALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast EventMay 20, 2025 | globenewswire.comALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025May 13, 2025 | globenewswire.comALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | finance.yahoo.comALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | globenewswire.com3ALXO : What's Next: ALX Oncology Holdings's Earnings PreviewMay 7, 2025 | benzinga.comALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025May 2, 2025 | globenewswire.comALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trialsApril 28, 2025 | finance.yahoo.comALX Oncology's Phase 2 Trials In Head & Neck Cancer Fail To Meet Primary EndpointsApril 27, 2025 | nasdaq.comEvorpacept fails to meet trial endpoints in HNSCCApril 26, 2025 | investing.comALX Oncology reports ASPEN-03, ASPEN-04 trials did not meet primary endpointsApril 26, 2025 | markets.businessinsider.comALX Oncology reports ‘encouraging’ final results from Phase 1 evorpacept trialApril 26, 2025 | markets.businessinsider.comALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin LymphomaApril 25, 2025 | globenewswire.comALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary EndpointsApril 25, 2025 | globenewswire.comALX Oncology receives IND clearance from FDA for ALX2004April 8, 2025 | markets.businessinsider.comALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug ConjugateApril 7, 2025 | markets.businessinsider.comALX Oncology (NASDAQ:ALXO) Price Target Cut to $1.50 by Analysts at Stifel NicolausMarch 8, 2025 | marketbeat.comALX Oncology files $364.12M mixed securities shelfMarch 8, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for ALX Oncology (NASDAQ:ALXO)March 8, 2025 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by BrokeragesMarch 8, 2025 | marketbeat.comALX Oncology Holdings Insider Trading Activity | NASDAQ:ALXO | BenzingaMarch 7, 2025 | benzinga.comALX Oncology (NASDAQ:ALXO) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPSMarch 7, 2025 | marketbeat.comALX Oncology (NASDAQ:ALXO) Given New $9.00 Price Target at Piper SandlerMarch 7, 2025 | marketbeat.comALX Oncology (NASDAQ:ALXO) Upgraded to "Buy" at Jefferies Financial GroupMarch 7, 2025 | marketbeat.comALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 6, 2025 | globenewswire.comBay Area biotech firm once worth more than $4B lays off 30% of staffMarch 6, 2025 | msn.comALX Oncology price target raised to $9 from $8 at Piper SandlerMarch 6, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)March 6, 2025 | markets.businessinsider.comALX Oncology upgraded to Buy from Hold at JefferiesMarch 6, 2025 | markets.businessinsider.comALX Oncology will highlight progress across its clinical pipelineMarch 5, 2025 | markets.businessinsider.comALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast EventMarch 5, 2025 | globenewswire.comALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025February 27, 2025 | globenewswire.comALX Oncology (ALXO) Projected to Post Earnings on ThursdayFebruary 27, 2025 | marketbeat.comALX Oncology to Host Virtual R&D Day on March 5, 2025February 18, 2025 | globenewswire.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesFebruary 11, 2025 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest UpdateJanuary 31, 2025 | marketbeat.comALX Oncology (NASDAQ:ALXO) Price Target Lowered to $2.20 at UBS GroupJanuary 27, 2025 | marketbeat.comHC Wainwright Comments on ALX Oncology FY2029 EarningsJanuary 27, 2025 | marketbeat.comALX Oncology price target lowered to $5 from $25 at H.C. WainwrightJanuary 25, 2025 | markets.businessinsider.comHold Rating for ALX Oncology Amid Mixed ASPEN-06 Study Results and Financial ConcernsJanuary 24, 2025 | markets.businessinsider.comStifel maintains hold on ALX Oncology shares, keeps $3 targetJanuary 24, 2025 | msn.comH.C. Wainwright cuts ALX Oncology target to $5, keeps buy ratingJanuary 24, 2025 | msn.comALX Oncology's (ALXO) Overweight Rating Reaffirmed at Cantor FitzgeraldJanuary 24, 2025 | marketbeat.comALX Oncology (NASDAQ:ALXO) Price Target Cut to $5.00 by Analysts at HC WainwrightJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Comments on ALX Oncology FY2025 EarningsJanuary 24, 2025 | marketbeat.comEvorpacept shows promise in HER2-positive cancer trialJanuary 23, 2025 | msn.comALX Oncology stock falls 16% amid Phase 2 data updateJanuary 23, 2025 | msn.com Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALXO Media Mentions By Week ALXO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALXO News Sentiment▼0.940.39▲Average Medical News Sentiment ALXO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALXO Articles This Week▼22▲ALXO Articles Average Week Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immuneering News Today FitLife Brands News Today Protara Therapeutics News Today Fate Therapeutics News Today Protalix BioTherapeutics News Today Inhibikase Therapeutics News Today ALT5 Sigma News Today Anebulo Pharmaceuticals News Today OKYO Pharma News Today Climb Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALXO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
